Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(2.22)
# 663
Out of 5,182 analysts
49
Total ratings
31.71%
Success rate
3.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GENB Generate Biomedicines | Initiates: Overweight | n/a | $11.41 | - | 1 | Mar 24, 2026 | |
| LEGN Legend Biotech | Maintains: Overweight | $75 → $74 | $18.16 | +307.49% | 3 | Dec 17, 2025 | |
| VSTM Verastem | Assumes: Overweight | n/a | $5.31 | - | 1 | Oct 16, 2025 | |
| ACLX Arcellx | Assumes: Neutral | $88 | $114.83 | -23.36% | 1 | Oct 9, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Overweight | n/a | $19.67 | - | 3 | Sep 8, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Overweight | n/a | $49.96 | - | 1 | Jul 17, 2025 | |
| PRTA Prothena Corporation | Reiterates: Neutral | n/a | $10.50 | - | 2 | Jun 20, 2025 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $10.43 | - | 4 | Apr 1, 2025 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $23.05 | - | 4 | Mar 20, 2025 | |
| BCAX Bicara Therapeutics | Reiterates: Overweight | $13 | $21.12 | -38.40% | 2 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.74 | - | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $51.22 | - | 4 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $96.07 | - | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $32.92 | - | 4 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $19.95 | - | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $31.05 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $172.97 | +68.82% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $436.27 | -15.19% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.94 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.75 | - | 1 | May 30, 2017 |
Generate Biomedicines
Mar 24, 2026
Initiates: Overweight
Price Target: n/a
Current: $11.41
Upside: -
Legend Biotech
Dec 17, 2025
Maintains: Overweight
Price Target: $75 → $74
Current: $18.16
Upside: +307.49%
Verastem
Oct 16, 2025
Assumes: Overweight
Price Target: n/a
Current: $5.31
Upside: -
Arcellx
Oct 9, 2025
Assumes: Neutral
Price Target: $88
Current: $114.83
Upside: -23.36%
Summit Therapeutics
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $19.67
Upside: -
Scholar Rock Holding
Jul 17, 2025
Initiates: Overweight
Price Target: n/a
Current: $49.96
Upside: -
Prothena Corporation
Jun 20, 2025
Reiterates: Neutral
Price Target: n/a
Current: $10.50
Upside: -
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $10.43
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $23.05
Upside: -
Bicara Therapeutics
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $21.12
Upside: -38.40%
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.74
Upside: -
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $51.22
Upside: -
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $96.07
Upside: -
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $32.92
Upside: -
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $19.95
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $31.05
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $172.97
Upside: +68.82%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $436.27
Upside: -15.19%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.94
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $2.75
Upside: -